Home › Leucemia › Massachusetts › Boston
Studi clinici su Leucemia a Boston, MA
25 studi su Leucemia cercano partecipanti presso sedi a Boston e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
In reclutamentoFase 2
- Dana-Farber Cancer Institute, Boston
Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
In reclutamento
- Dana-Farber Cancer Institute, Boston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
In reclutamentoFase 3
- Research Site, Boston
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
In reclutamentoFase 2
- Massachusetts General Hospital, Boston
CIML NK Cells With Venetoclax for AML
In reclutamentoFase 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
In reclutamentoFase 1
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
In reclutamentoFase 1
- Beth Israel Deaconess Medical Center, Boston
ALL Backbone in AYAs
In reclutamentoFase 2
- Dana Farber Cancer Institute, Boston
Addressing Cancer Care Equity With Social Determinants of Health Screening and Early Intervention
In reclutamento
- Mass General Brigham Cancer Institute, Boston
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
In reclutamentoVolontari sani benvenuti
- Dana-Farber Cancer Institute, Boston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
In reclutamentoFase 1/2
- Dren Investigational Site, Boston
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
In reclutamentoFase 1
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
In reclutamentoFase 1
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
In reclutamentoFase 1
- Dana-Farber Cancer Institute, Boston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
In reclutamentoStudio osservazionale
- Dana-Farber Cancer Institute, Boston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
In reclutamentoFase 2/3
- Dana-Farber Cancer Institute, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
In reclutamento
- Massachusetts General Hospital Cancer Center, Boston
Shwachman Diamond Syndrome Registry and Study
In reclutamentoStudio osservazionale
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Revumenib in Combination With 7+3 + Midostaurin in AML
In reclutamentoFase 1
- Dana-Farber Cancer Institute, Boston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
In reclutamentoFase 1
- Massachusetts General Hospital, Boston
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
In reclutamentoFase 1/2
- Dana-Farber Cancer Institute, Boston
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
In reclutamentoFase 1/2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Mosunetuzumab for CLL MRD Clearance
In reclutamentoFase 1/2
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
In reclutamento
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
HEME Home Transfusion Program
In reclutamento
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Studi su Leucemia in altre città
- Houston, TX28 studi
- New York City, NY19 studi
- Chicago, IL16 studi
- Los Angeles, CA16 studi
- Durham, NC13 studi
- Columbus, OH12 studi
- Nashville, TN12 studi
- Baldwin Park, CA12 studi
- Philadelphia, PA12 studi
- Milwaukee, WI11 studi
- Atlanta, GA11 studi
- Seattle, WA11 studi
Altri studi a Boston
- Cancro al seno111 studi
- Cancro del polmone non a piccole cellule89 studi
- Cancro (tutti i tipi)86 studi
- Cancro colorettale63 studi
- Cancro metastatico63 studi
- Cancro ai polmoni62 studi
- Cancro ovarico61 studi
- Cancro alla prostata60 studi
- Depressione52 studi
- Cancro dell'endometrio50 studi
- Leucemia mieloide acuta44 studi
- Cancro pancreatico44 studi
Fonte: ClinicalTrials.gov, dati recuperati il 2 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.